Guozhang Xu

848 citations

34 papers · 665 indexed · h-index 16

Co-authors: Lawrence M. Sayre Yahu A. Liu Weihan Zhang Quan Yuan Stuart L. Emanuel Peter J. Connolly Mary Adams Steven A. Middleton
Topics: Diabetes Treatment and Management (6 papers)HER2/EGFR in Cancer Research (4 papers)HIV/AIDS drug development and treatment (4 papers)
Cited by: Biochemistry Organic Chemistry Pharmaceutical Science
Journals: Cancer Research Journal of Medicinal Chemistry The Journal of Organic Chemistry
Partner nations: United States China Belgium

In The Last Decade

Guozhang Xu

33 papers receiving 659 citations

Peers

Countries citing papers authored by Guozhang Xu

Since Specialization

Citations

This map shows the geographic impact of Guozhang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guozhang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guozhang Xu more than expected).

Fields of papers citing papers by Guozhang Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guozhang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guozhang Xu. The network helps show where Guozhang Xu may publish in the future.

Co-authorship network of co-authors of Guozhang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Guozhang Xu. A scholar is included among the top collaborators of Guozhang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guozhang Xu. Guozhang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action 2021 ·Frontiers in Endocrinology ·(unknown),Jenson Qi,Guozhang Xu,Matthew M. Rankin,(unknown),June Xu,(unknown),Alessandro Pocai	4
2	5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors 2020 ·Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,Fuyong Du,Gee‐Hong Kuo,June Xu,Yin Liang,Keith T. Demarest,Michael D. Gaul	10
3	Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor 2020 ·Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,Michael D. Gaul,Zhi‐Jie Liu,Renée L. DesJarlais,Jenson Qi,Weixue Wang,Daniel J. Krosky,Ioanna P. Petrounia,Cynthia Milligan,An N. Hermans,(unknown),(unknown),June Xu,John Spurlino	3
4	Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes 2019 ·Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,Michael D. Gaul,Fengbin Song,Fuyong Du,Yin Liang,Renée L. DesJarlais,(unknown),Brian C. Shook,(unknown),(unknown),Annette Eckardt,Keith T. Demarest	3
5	Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists 2019 ·Bioorganic & Medicinal Chemistry Letters ·Fengbin Song,Guozhang Xu,Michael D. Gaul,Baoping Zhao,Tianbao Lu,Rui Zhang,Renée L. DesJarlais,(unknown),Norman Huebert,Brian C. Shook,(unknown),(unknown),Annette Eckardt,Keith T. Demarest	18
6	Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors 2018 ·Bioorganic & Medicinal Chemistry Letters ·Gee‐Hong Kuo,Micheal D. Gaul,Yin Liang,June Xu,Fuyong Du,Pamela J. Hornby,Guozhang Xu,Jenson Qi,Nathaniel Wallace,Seung‐Hun Lee,Eugene B. Grant,William V. Murray,Keith T. Demarest	29
7	Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents 2017 ·European Journal of Medicinal Chemistry ·Raymond J. Patch,Hui Huang,Sharmila Patel,Wing S. Cheung,Guozhang Xu,Baoping Zhao,Derek A. Beauchamp,Dionisios Rentzeperis,John G. Geisler,(unknown),Jianying Liu,Jyotsna Kasturi,(unknown),Micheal D. Gaul,Mark R. Player	30
8	Economic burden estimation for pandemic hand foot and mouth disease in Ningbo City,2011 2012 ·Guozhang Xu	2
9	Maternal-infant pairs comparative study on the change of maternal transferred measles antibody level in infants 2008 ·Chinese Journal of Public Health ·Guozhang Xu	3
10	Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases 2008 ·Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,(unknown),Terry V. Hughes,(unknown),Peter J. Connolly,M.C. Abad,Michael P. Neeper,Geoffrey T. Struble,Barry A. Springer,Stuart L. Emanuel,Robert H. Gruninger,Niranjan B. Pandey,Mary Adams,(unknown),Angel R. Fuentes‐Pesquera,Steven A. Middleton,Lee M. Greenberger	48
11	Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif 2008 ·Bioorganic & Medicinal Chemistry Letters ·K. D. Kreutter,Tianbao Lu,Lily Lee,Edward C. Giardino,Sharmila Patel,Hui Huang,Guozhang Xu,Mark Fitzgerald,Barbara J. Haertlein,V. Mohan,Carl Crysler,Stephen Eisennagel,Malini Dasgupta,Martin McMillan,John Spurlino,Norman Huebert,Bruce E. Maryanoff,Bruce E. Tomczuk,Bruce P. Damiano,Mark R. Player	24
12	A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity 2008 ·Bioorganic & Medicinal Chemistry Letters ·Terry V. Hughes,Guozhang Xu,Steven K. Wetter,Peter J. Connolly,Stuart L. Emanuel,Prabha Karnachi,Scott R. Pollack,Niranjan B. Pandey,Mary Adams,(unknown),Steven A. Middleton,Lee M. Greenberger	24
13	4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,M.C. Abad,Peter J. Connolly,Michael P. Neeper,Geoffrey T. Struble,Barry A. Springer,Stuart L. Emanuel,Niranjan B. Pandey,Robert H. Gruninger,Mary Adams,(unknown),Angel R. Fuentes‐Pesquera,Steven A. Middleton	80
14	4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Micheal D. Gaul,Guozhang Xu,(unknown),Heidi M. Ott,Christian A. Baumann	15
15	Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Shenlin Huang,Ronghua Li,Peter J. Connolly,Guozhang Xu,Michael D. Gaul,Stuart L. Emanuel,Kenneth R. LaMontagne,Lee M. Greenberger	21
16	Synthesis of alkenyldiarylmethane (ADAM) non-Nucleoside HIV-1 reverse transcriptase inhibitors with non-Identical aromatic rings 2002 ·Bioorganic & Medicinal Chemistry ·Guozhang Xu,Tracy L. Hartman,(unknown),Jim A. Turpin,Robert W. Buckheit,Mark Cushman	17
17	Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents 2002 ·Bioorganic & Medicinal Chemistry ·Guozhang Xu,(unknown),Tracy L. Hartman,(unknown),Karen Watson,Jim A. Turpin,Robert W. Buckheit,Allison A. Johnson,Yves Pommier,Mark Cushman	11
18	Cross-Linking of Proteins by 3-(Trifluoromethyl)-2,5-hexanedione. Model Studies Implicate an Unexpected Amine-Dependent Defluorinative Substitution Pathway Competing with Pyrrole Formation 2002 ·The Journal of Organic Chemistry ·Guozhang Xu,Lawrence M. Sayre	6
19	Studies of Risk Factors on Toxoplasma Gondii Infection in Maternal Women and Newborn Infants 2001 ·China Public Health ·Guozhang Xu	1
20	The Biological Effects of Structural Variation at the Meta Position of the Aromatic Rings and at the End of the Alkenyl Chain in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors 2001 ·Journal of Medicinal Chemistry ·Guozhang Xu,(unknown),(unknown),Tracy L. Hartman,(unknown),(unknown),(unknown),Jim A. Turpin,Robert W. Buckheit,Mark Cushman	28

About Guozhang Xu

Guozhang Xu is a scholar working on Biochemistry, Virology and Toxicology, having authored 34 papers that have together received 665 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (6 papers), HER2/EGFR in Cancer Research (4 papers) and HIV/AIDS drug development and treatment (4 papers). The work is most often cited by research in Biochemistry (76 citations), Organic Chemistry (296 citations) and Pharmaceutical Science (28 citations). Guozhang Xu has collaborated with scholars based in United States, China and Belgium. Frequent co-authors include Lawrence M. Sayre, Yahu A. Liu, Weihan Zhang, Quan Yuan, Stuart L. Emanuel, Peter J. Connolly, Mary Adams, Steven A. Middleton, Robert W. Buckheit and Jim A. Turpin. Their work appears in journals such as Cancer Research, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact